AGC Biologics, Molecular Partners to Develop Anti-COVID-19 DARPin Program

AGC Biologics is partnering with clinical-stage biotech company Molecular Partners to develop a new class of custom-built protein therapeutics known as DARPin®. AGC Biologics and Molecular Partners AG will work together to develop their multi-specific DARPin anti-COVID-19 program, MP0420. Molecular Partners AG plans to initiate clinical studies for this program in the second half of 2020.

AGC Biologics will manufacture at 100 liter and 1,000 liter scales, which is suitable for development and initial global supply for patients in need. Based upon preliminary potency data, a subcutaneous administration of MP0420 could function as both a therapeutic for existing viral infection and as a potential preventive therapy.

"Securing manufacturing capacity is a critical step in advancing our novel antiviral DARPin program to clinical readiness. We are highly committed to move to patients as rapidly as possible, building upon our strong preclinical data that shows potential best in class potency in neutralizing live virus," said Patrick Amstutz, CEO of Molecular Partners. "We are greatly encouraged by the recent data supporting the potential of our unique tri-specific approach to target SARS-CoV-2, as we believe novel therapeutics will be an essential tool for addressing the global COVID-19 pandemic."

"AGC Biologics is pleased to be working with Molecular Partners on such an essential and innovative program," said AGC Biologics CBO Mark Womack. "We are very proud to work alongside Molecular Partners in the fight against COVID-19."